×
About 213,176 results

ALLMedicine™ Detailed topics Center - News

Is Sentinel Lymph Node Biopsy Alone Oncologically Safe for Patients With Early-Stage Cervical Cancer?
https://ascopost.com/news/may-2020/is-sentinel-lymph-node-biopsy-alone-oncologically-safe-for-patients-with-early-stage-cervical-cancer/

May 29th, 2020 - In a study of patients with early-stage cervical cancer presented by Balaya et al during the Gynecologic Cancer Oral Abstract Session of the ASCO20 Virtual Scientific Program (Abstract 6006), researchers assessed disease-free and disease-specific survival to determine whether sentinel lymph node biopsy alone was a valid standard of care, or if bilateral pelvic lymphadenectomy—the current “gold ...

Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib
https://ascopost.com/videos/asco20-virtual-scientific-program/scott-kopetz-on-encorafenib-plus-cetuximab-with-or-without-binimetinib-in-colorectal-cancer/

May 29th, 2020 - Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard chemotherapy, encorafenib plus cetuximab with or without binimetinib improved overall survival and objective response rate in previously treated patients with BRAF V600E–mutated metastatic colorectal cancer (Abstract 4001).

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Drunkorexia: An investigation of symptomatology and early maladaptive schemas within a female, young adult Australian population
https://aps.onlinelibrary.wiley.com/doi/abs/10.1111/ap.12462
Australian Psychologist;

Drunkorexia is a trend on the rise within the young adult population with significant physical, psychological, and social health implications. Many studies have investigated the link between Early Maladaptive Schemas (EMS) and both eating disorders and substance misuse. To date, no studies have specifically focused on EMS amongst those with Drunkorexia behaviours. The main objectives of this st...

Drunkorexia: A new entity and the emergence of a new danger in young people. Drink or eat, they chose. A case report
https://www.sciencedirect.com/science/article/pii/S0985056220300200
Nutrition Clinique Et Métabolisme;

Eating disorders (ED) are common, severe and prevalent in young women. They share common clinical, neurobiological and psychopathological processes with other addictive behaviors. Binge drinking is also a growing behavior among young people, creating major risks. In parallel to these existing disorders, we have seen the arrival of new clinical phenomenon called “drunkorexia”, which is of intere...

HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
https://ascopost.com/news/may-2020/hif2a-inhibitor-for-von-hippel-lindau-disease-associated-renal-cell-carcinoma/

May 29th, 2020 - In an international trial, treatment with MK-6482, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease–associated renal cell carcinoma (RCC).

Fatima Cardoso, MD, on Breast Cancer: MammaPrint as Guidance for Adjuvant Chemotherapy
https://ascopost.com/videos/asco20-virtual-scientific-program/fatima-cardoso-on-mammaprint-as-guidance-for-adjuvant-chemotherapy/

May 29th, 2020 - Fatima Cardoso, MD, of Lisbon’s Champalimaud Cancer Center, discusses the long-term results of MINDACT, a large prospective trial showing the clinical utility of the 70-gene signature MammaPrint for adjuvant chemotherapy decision-making. The primary distant metastasis–free survival endpoint at 5 years continued to be met in chemotherapy-untreated women with clinical-high/genomic-low risk diseas...

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/jeffrey-meyerhardt-on-celecoxib-and-folfox-for-stage-iii-colon-cancer/

May 29th, 2020 - Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard chemotherapy did not significantly improve disease-free or overall survival (Abstract 4003).

Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
https://ascopost.com/news/may-2020/transoral-resection-followed-by-low-dose-radiation-for-some-oropharyngeal-cancers/

May 29th, 2020 - The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing transoral robotic surgery, tested reduced postoperative radiation therapy in patients with human papillom...

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
https://ascopost.com/news/may-2020/first-line-pembrolizumab-plus-etoposideplatinum-for-extensive-stage-small-cell-lung-cancer/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-stage small cel...

Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone
https://ascopost.com/videos/asco20-virtual-scientific-program/shaji-kumar-on-carfilzomib-lenalidomide-bortezomib-and-dexamethasone-in-multiple-myeloma/

May 29th, 2020 - Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial, which showed bortezomib, lenalidomide, and dexamethasone should remain the standard of care in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, for whom early autologous stem cell transplant is not intended (Abstract LBA3).

Nancy U. Lin, MD, on Metastatic Breast Cancer: Tucatinib, Trastuzumab, and Capecitabine
https://ascopost.com/videos/asco20-virtual-scientific-program/nancy-lin-on-tucatinib-trastuzumab-and-capecitabine-for-metastatic-breast-cancer/

May 29th, 2020 - Nancy U. Lin, MD, of Dana-Farber Cancer Institute, discusses the HER2CLIMB study of patients with previously treated HER2-positive metastatic breast cancer that had metastasized to the brain. Adding tucatinib to trastuzumab and capecitabine doubled the intracranial response rate and reduced the risk of death by nearly half, compared with trastuzumab plus capecitabine (Abstract 1005).

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 28th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Adjuvant Osimertinib ‘Exceeds Expectations’ in Early-Stage EGFR-Positive NSCLC
https://ascopost.com/news/may-2020/adjuvant-osimertinib-exceeds-expectations-in-egfr-positive-nsclc/

May 27th, 2020 - Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA ­EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. These results from the first interim analysis of the phase III ADAURA trial were reported at the ASCO20 Virtual Scientific Program and f...

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage Ib–IIIa EGFR Mutation–Positive Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/roy-herbst-on-osimertinib-in-stage-ib-iiia-egfr-mutation-positive-nsclc/

May 29th, 2020 - Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).

New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200180/full/

May 28th, 2020 - DESKTOP III became the first phase III, prospective, randomized trial to show an association between improved overall survival (OS) and secondary cytoreductive surgery in women with platinum-sensitive recurrent ovarian cancer (PSROC), offering hope for people with a condition that results in nearly 14,000 deaths annually. Data were presented during the ASCO20 Virtual Scientific Program (Abstrac...

Palliative Care Improves Well-Being and QoL in Phase I Cancer Trial Participants
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200184/full/

May 28th, 2020 - Participants in phase I oncology trials represent a patient population new to palliative care. These patients typically have remarkable symptoms, with a symptom burden comparable to other patients with cancer.1 Thomas J. Smith, MD, FASCO, of Johns Hopkins University, presented the results of a randomized trial evaluating a palliative care intervention (PCI) compared with usual care (UC) for pat...

Effect of Veliparib With or Without Cisplatin in Breast Cancer: Results of SWOG S1416
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200176/full/

May 28th, 2020 - The Southwest Oncology Group (SWOG) 1416 phase II trial was designed to compare the efficacy of the PARP inhibitor veliparib plus cisplatin versus cisplatin alone in patients with metastatic and/or locally recurrent triple-negative breast cancer (TNBC) or BRCA1 or BRCA2 germline mutation–associated HER2-negative metastatic breast cancer. Priyanka Sharma, MD, of the University of Kansas Medical ...

Pembrolizumab Monotherapy Demonstrates PFS Benefit Over Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200193/full/

May 28th, 2020 - Pembrolizumab monotherapy demonstrated a progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, according to the results from the phase III international KEYNOTE-204 trial (Abstract 8005). Clinically meaningful improvement in PFS was observed in all subgroups tested, including patients who did not receive a...

Sentinel Node Biopsy Strategy Equivalent to Neck Dissection in T1-T2NO Oropharyngeal and Oral Cancers
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200192/full/

May 28th, 2020 - In a randomized multicenter study, a strategy based on sentinel node biopsy (SNB) was equivalent to elective neck dissection (END) in the management of T1-T2N0 oral and oropharyngeal squamous cell carcinomas, with comparable 2-year neck recurrence-free survival (RFS) and lower morbidity in year 1 after surgery (Abstract 6501). Renaud Garrel, MD, of CHU Montpellier, France, presented the results...